45 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of KDM5A inhibitors: Homology modeling, virtual screening and structure-activity relationship analysis.
Sichuan University
Identification of SNAIL1 Peptide-Based Irreversible Lysine-Specific Demethylase 1-Selective Inactivators.
Kyoto Prefectural University of Medicine
Docking and Linking of Fragments To Discover Jumonji Histone Demethylase Inhibitors.
University of Oxford
Identification of Jumonji AT-Rich Interactive Domain 1A Inhibitors and Their Effect on Cancer Cells.
Kyoto Prefectural University of Medicine
Small-molecule ligands of methyl-lysine binding proteins: optimization of selectivity for L3MBTL3.
University of North Carolina At Chapel Hill
Identification of the KDM2/7 histone lysine demethylase subfamily inhibitor and its antiproliferative activity.
Kyoto Prefectural University of Medicine
From Hit Seeking to Magic Bullets: The Successful Union of Epigenetic and Fragment Based Drug Discovery (EPIDD + FBDD).
University of S£O Paulo
Recent Advances with KDM4 Inhibitors and Potential Applications.
St. Jude Children'S Research Hospital
Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present).
Hangzhou Normal University
Discovery of a new class of JMJD6 inhibitors and structure-activity relationship study.
Nankai University
Discovery of a potent and selective inhibitor of histone lysine demethylase KDM4D.
Nankai University
Discovery of pyrazole derivatives as cellular active inhibitors of histone lysine specific demethylase 5B (KDM5B/JARID1B).
Zhengzhou University
Lead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies.
Genentech
Identification of novel lysine demethylase 5-selective inhibitors by inhibitor-based fragment merging strategy.
Kyoto Prefectural University of Medicine
Identification of ortho-hydroxy anilide as a novel scaffold for lysine demethylase 5 inhibitors.
Kyoto Prefectural University of Medicine
Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor.
University of Oxford
The structure-activity relationships of L3MBTL3 inhibitors: flexibility of the dimer interface.
University of North Carolina
Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A.
The University of Texas M.D. Anderson Cancer Center
Methyllysine binding domains: Structural insight and small molecule probe development.
University of Connecticut
Investigations on small molecule inhibitors targeting the histone H3K4 tri-methyllysine binding PHD-finger of JmjC histone demethylases.
University of Oxford
From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors.
Genentech
Insights into the Action of Inhibitor Enantiomers against Histone Lysine Demethylase 5A.
The University of Texas M.D. Anderson Cancer Center
Discovery of pyrazolo[1,5-a]pyrimidine-3-carbonitrile derivatives as a new class of histone lysine demethylase 4D (KDM4D) inhibitors.
Sichuan University
Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors
Zhejiang Dtrm Biopharma
Price for Opening the Transient Specificity Pocket in Human Aldose Reductase upon Ligand Binding: Structural, Thermodynamic, Kinetic, and Computational Analysis.
Philipps-Universität Marburg
Roles of phosphate recognition in inositol 1,3,4,5,6-pentakisphosphate 2-kinase (IPK1) substrate binding and activation.
Mcgill University
Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities
Almirall
A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate.
Whitehead Institute For Biomedical Research
Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
Merck Sharp & Dohme